恶性胸膜间皮瘤的研究进展

doi:10.3760/cma.j.issn.1673-422X.2015.06.017

摘要/Abstract

摘要： 恶性胸膜间皮瘤（MPM）是起源于胸膜间皮细胞的一种恶性肿瘤。MPM的诊断主要依靠胸膜活检与免疫组织化学检查。MPM的治疗应以手术加放疗、化疗、免疫治疗等综合治疗为主。手术治疗的主要术式有胸膜外全肺切除术和胸膜部分剥脱术。放疗以三维适形为主。化疗以顺铂和培美曲塞为标准。免疫治疗的主要靶点有调节性T细胞、细胞毒性T淋巴细胞相关抗原4、程序性死亡分子1配体等。

关键词: 间皮瘤, 治疗, 免疫系统, 血液学

Abstract: Malignant pleural mesothelioma (MPM) is a malignant cancer originated from pleural mesothelial cell. The diagnosis of MPM is based on biopsy of pleura and immunohistochemistry. The current treatment of MPM is multimodality therapy including surgery, radiotherapy, chemotherapy and immunotherapy. There are two major surgical procedures: extrapleural pneumonectomy and pleurectomy/decortication. The main of radiotherapy is threedimensional conformal radiotherapy. Cisplatinum combined with pemetrexed is the firstline chemotherapy for the patients with MPM. The principal targets for immunotherapy include regulatory T cells, cytotoxic T lymphocyte associated antigen 4 and PD 1.

Key words: Mesothelioma, Therapy, Immune system, Hematology

武新舒,赵小刚,武利存,丛波. 恶性胸膜间皮瘤的研究进展[J]. 国际肿瘤学杂志, 2015, 42(6): 462-465.

Wu Xinshu, Zhao Xiaogang, Wu Licun, Cong Bo. Advances of malignant pleural mesothelioma[J]. Journal of International Oncology, 2015, 42(6): 462-465.

参考文献

［1］ Cihan YB, Ozturk A, Arslan A, et al. ERCC1 as a biological marker guiding management in malignant pleural mesothelioma［J］. Asian Pac J Cancer Prev, 2014, 15(10): 4117-4123. ［2］ Neumann V, Loseke S, Nowak D, et al. Malignant pleural mesothelioma: incidence, etiology, diagnosis, treatment, and occupational health［J］. Dtsch Arztebl Int, 2013, 110(18): 319-326. ［3］ Acton V. Preventing pleural mesothelioma in patients with recognizable asbestosrelated pleural plaques［J］. J Thorac Cardiovasc Surg, 2014, 148(4): 1763. ［4］ Linton A, Pavlakis N, O′Connell R, et al. Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales［J］. Br J Cancer, 2014, 111(9): 1860-1869. ［5］ Kanbay A, Ozer SZ, Tutar N, et al. Nonasbestosrelated malignant pleural mesothelioma［J］. Intern Med, 2014, 53(17): 1977-1979. ［6］ MenendezNavarro A, Lopez RC. Asbestosrelated occupational cancers compensated under the Spanish National Insurance System, 1978—2011［J］. Int J Occup Environ Health, 2014, 21(1): 31-39. ［7］ Husain AN, Colby T, Ordonez N, et al. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group［J］. Arch Pathol Lab Med, 2013, 137(5): 647-667. ［8］ Szulkin A, Otvs R, Hillerdal CO, et al. Characterization and drug sensitivity profiling of primary malignant mesothelioma cells from pleural effusions［J］. BMC Cancer, 2014, 14: 709. ［9］ Kao SC, Klebe S, Henderson DW, et al. Low calretinin expression and high neutrophiltolymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy［J］. J Thorac Oncol, 2011, 6(11): 1923-1929. ［10］ Klebe S, Brownlee NA, Mahar A, et al. Sarcomatoid mesothelioma: a clinicalpathologic correlation of 326 cases［J］. Mod Pathol, 2010, 23(3): 470-479. ［11］ Takeshima Y, Amatya VJ, Kushitani K, et al. Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma［J］. Histopathology, 2009, 54(6): 667-676. ［12］ Lovato A, Marioni G, Manzato E, et al. Elderly patients at higher risk of laryngeal carcinoma recurrence could be identified by a panel of two biomarkers (nm23 H1 and CD105) and pN+ status［J］. Eur Arch Otorhinolaryngol, 2014, In press. ［13］ Cristaudo A, Bonotti A, Simonini S, et al. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma［J］. J Thorac Oncol, 2011, 6(9): 1587-1593. ［14］ Ostroff RM, Mehan MR, Stewart A, et al. Early detection of malignant pleural mesothelioma in asbestosexposed individuals with a noninvasive proteomicsbased surveillance tool［J］. PLoS One, 2012, 7(10): e46091. ［15］ Bayram M, Dongel I, Akbas A, et al. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos［J］. Lung, 2014, 192(1): 197-203. ［16］ Rosenzweig KE. Current readings: improvements in intensitymodulated radiation therapy for malignant pleural mesothelioma［J］. Semin Thorac Cardiovasc Surg, 2013, 25(3): 245-250. ［17］ Papaspyros S, Papaspyros S. Surgical management of malignant pleural mesothelioma: impact of surgery on survival and quality of liferelation to chemotherapy, radiotherapy, and alternative therapies［J］. ISRN Surg, 2014, 2014: 817203. ［18］ Rena O, Casadio C. Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure［J］. Lung Cancer, 2012, 77(1): 151-155. ［19］ Martin JT, Zwischenberger BA, Fabian T. Malignant pleural mesothelioma: treatment options and novel therapies［J］. J Cancer Ther, 2014, 5(1): 60-66. ［20］ Opitz I. Management of malignant pleural mesotheliomathe European experience［J］. J Thorac Dis, 2014, 6 Suppl 2: S238-252. ［21］ Cho BC, Feld R, Leighl N, et al. A feasibility study evaluating surgery for mesothelioma after radiation therapy: the "SMART″ approach for resectable malignant pleural mesothelioma［J］. J Thorac Oncol, 2014, 9(3): 397-402. ［22］ Van Schil PE, Opitz I, Weder W, et al. Multimodal management of malignant pleural mesothelioma: where are we today?［J］. Eur Respir J, 2014, 44(3): 754-764. ［23］ Nuvoli B, Santoro R, Catalani S, et al. Cellfood induces apoptosis in human mesothelioma and colorectal cancer cells by modulating p53, c-myc and pAkt signaling pathways［J］. J Exp Clin Cancer Res, 2014, 33: 24. ［24］ Anraku M, Tagawa T, Wu L, et al. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma［J］. J Immunol, 2010, 185(2): 956-966. ［25］ Wu L, Yun Z, Tagawa T, et al. Tumor cell repopulation between cycles of chemotherapy is inhibited by regulatory T cell depletion in a murine mesothelioma model［J］. J Thorac Oncol, 2011, 6(9): 1578-1586. ［26］ Xu P, Chen H, Chen YJ, et al. Expression of PD-1/PD-L1 in peripheral blood mononuclear cells in lung cancer patients and its biological significance［J］. Zhonghua Zhong Liu Za Zhi, 2013, 35(12): 910-913. ［27］ Wei T, Zhang J, Wu Y, et al. Expression levels of coinhibitory molecules CTLA4, LAG3, PD1 and CD39 on CD4+ T cells correlate with progression of nonsmall cell lung cancer［J］. Zhonghua Zhong Liu Za Zhi, 2014, 36(6): 424-429. ［28］ Wu L C, Yun Z H, Tagawa T, et al. CTLA4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma［J］. Mol Cancer Ther, 2012, 11(8): 1809-1819.

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	张百红, 岳红云. 新作用机制的抗肿瘤药物进展[J]. 国际肿瘤学杂志, 2024, 51(6): 354-358.
[4]	许凤琳, 吴刚. EBV在鼻咽癌肿瘤免疫微环境和免疫治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 359-363.
[5]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[6]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[7]	王昆, 周中新, 臧其威. 血清TGF-β1、VEGF水平对非小细胞肺癌患者单孔胸腔镜根治术后复发的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 198-203.
[8]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[9]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[10]	王子豪, 王宇, 杨鑫, 何艺, 莫兴奎, 袁涛. 铁死亡在骨肉瘤中的分子机制及相关治疗的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 239-244.
[11]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[12]	严爱婷, 王翠竹, 刘春桂, 鲁小敏. 卡瑞利珠单抗与信迪利单抗治疗晚期非小细胞肺癌的临床疗效及安全性分析[J]. 国际肿瘤学杂志, 2024, 51(3): 137-142.
[13]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[14]	岳红云, 张百红. 肿瘤的分化治疗[J]. 国际肿瘤学杂志, 2024, 51(2): 109-113.
[15]	姜溪, 武永存, 梁艳, 楚丽, 段颖欣, 王力军, 霍俊杰. 派安普利单抗联合化疗对晚期非小细胞肺癌患者血管生成及循环内皮细胞的影响[J]. 国际肿瘤学杂志, 2024, 51(2): 89-94.